Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. DocuSign, Inc.
  6. News
  7. Summary
    DOCU   US2561631068

DOCUSIGN, INC.

(DOCU)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

DocuSign : Introducing Kim, Quality Assurance Quality Assurance Specialist at DKMS

07/28/2021 | 04:14pm EDT

For those suffering with blood cancer, a bone marrow or stem cell transplant is the best chance for survival. For this spotlight, we're pleased to introduce you to Kim Sivananthan, who works tirelessly behind the scenes at DKMS to help give patients a new lease on life.

DKMS was founded in 1991 after one family's struggle to find a lifesaving bone marrow donor. Today, it's the largest donor center and advocacy organization in the world-with over 1.3 million new potential donors registered every year.

It's that dedication to purpose that attracted Kim to the organization when she joined the quality assurance team in 2017.

We talked to Kim about what it's like working for an organization that's saved countless lives and her passion for using technology-like DocuSign for Life Sciences -to maintain regulatory compliance, and accelerate donor clearances.

How did you get your start as a quality assurance specialist?

I have a varied employment history. I got my master's degree in public health-and I started getting more interested in regulation, inspection and compliance. When my husband and I moved to New York City, I worked for the USDA as a compliance inspector for a few years-but the scheduling was really hectic for me. The quality management program at DKMS was relatively new, so I saw an opportunity there for career and professional growth.

What do you love most about your role?

Being able to work in process improvement and forging relationships. The people who work for DKMS are really passionate about the cause and the work they're doing to ultimately provide second chances of life for people. So, while my initial draw was a professional interest in process improvement-and having the ability to get in on the ground floor-what kept me there (even now as a consultant) is the passion of the people who work there.

What led you down the path to DocuSign eSignature?

Our primary donor requests from transplant centers are for 18-24 year olds. They're very often in college; sometimes they're working a job or two or maybe even beginning a family. Getting all of the required paper documentation back from these digital natives was really challenging and starting to affect our conversion rate from when a donor was requested to whether or not they actually donated. So, we started researching electronic options.

Since you're in such a heavily regulated industry, were there any compliance concerns or requirements that factored into your decision to use DocuSign?

DKMS is beholden to 21 CFR Part 11, which is around electronic records for products that fall in the FDA's wheelhouse. After sourcing a few different products and doing the demos with the DocuSign modules for 21 CFR Part 11, we thought: This is really great. I pitched it to our CEO, and then she pitched it to DKMS Germany. There were a lot of stakeholder meetings, a lot more pitching... but in late 2018, we purchased DocuSign's Life Sciences Modules for 21 CFR Part 11 and a standard DocuSign account for other use cases.

What are using DocuSign for today?

Since we rolled out DocuSign, we've seen a lot of interest across the organization. We're using it for all of our informed consents, health history screening questionnaires, medical suitability and eligibility paperwork, media release consent forms and even volunteer agreements. We've only increased our use.

What kind of feedback have you gotten from external users like the physicians you partner with at DKMS?

They love DocuSign. They literally pull out their phones on their lunch breaks, review all of the donor medical files, and electronically sign the eligibility forms the same day. Before DocuSign, we had 34 days between the time that a donor was declared eligible and we had a wet signature in hand. Now, it's less than 24 hours-no more printing or scanning or overnighting paper documents.

Read more about how DKMS streamlines compliance and donor outreach with DocuSign eSignature.

Disclaimer

DocuSign Inc. published this content on 26 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 July 2021 20:13:12 UTC.


ę Publicnow 2021
All news about DOCUSIGN, INC.
09/23DOCUSIGN : 3 Ways to Provide Secure ID Verification Without Disrupting the Customer Experi..
PU
09/23DOCUSIGN : Driving Process Efficiencies with DocuSign and QuickBooks Online Advanced
PU
09/23COMMITTING TO CUSTOMERS : Q&A With Lambert Walsh, DocuSign SVP Customer Success
PU
09/22DOCUSIGN : And the award goes to…the DocuSign eSignature REST API
PU
09/22DOCUSIGN : Getting an authentication token using the Bash Quickstart
PU
09/21INSIDER SELL : Docusign
MT
09/20FROM THE TRENCHES : Using DocuSign Connect with the eSignature SOAP API
PU
09/17DOCUSIGN : 4 Ways to Get the Most Out of Your Free DocuSign Account
PU
09/15INSIDER SELL : Docusign
MT
09/15DOCUSIGN : Delight Your Customers by Digitizing Insurance Claims
PU
More news
Analyst Recommendations on DOCUSIGN, INC.
More recommendations
Financials (USD)
Sales 2022 2 086 M - -
Net income 2022 -95,1 M - -
Net cash 2022 365 M - -
P/E ratio 2022 -535x
Yield 2022 -
Capitalization 53 842 M 53 842 M -
EV / Sales 2022 25,6x
EV / Sales 2023 19,6x
Nbr of Employees 5 630
Free-Float 97,8%
Chart DOCUSIGN, INC.
Duration : Period :
DocuSign, Inc. Technical Analysis Chart | DOCU | US2561631068 | MarketScreener
Technical analysis trends DOCUSIGN, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 20
Last Close Price 273,70 $
Average target price 328,23 $
Spread / Average Target 19,9%
EPS Revisions
Managers and Directors
Daniel D. Springer President, Chief Executive Officer & Director
Cynthia Gaylor Chief Financial Officer
Mary Agnes Wilderotter Chairman
Kamal Hathi Chief Technology Officer
Shanthi Iyer Chief Information Officer
Sector and Competitors
1st jan.Capi. (M$)
DOCUSIGN, INC.23.12%53 842
ORACLE CORPORATION36.71%244 848
SAP SE14.57%170 050
INTUIT INC.48.16%157 675
SERVICENOW, INC.20.67%131 605
CONSTELLATION SOFTWARE INC.32.90%36 737